Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.

Slides:



Advertisements
Similar presentations
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Advertisements

Advanced Heart Failure and the Role of Mechanical Circulatory Support
Optimizing Treatment Of Heart Failure for individual patients By Prof. Mansoor Ahmad FRCP Consultant Cardiologist.
HEART FAILURE: ANSWERS YOU NEVER GET TO QUESTIONS YOU ALWAYS ASK BART COX, M.D.FACC DIRECTOR, ADVANCED HEART FAILURE PROGRAM ASSOCIATE PROFESSOR OF MEDICINE.
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.
Congestive heart failure
Jim Hoehns, Pharm.D.. ClassificationEF (%)Description HF with reduced EF (HFrEF) ≤40 “systolic HF”; RCTs have mainly enrolled these HF patients; only.
Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate Medical Group Heart Failure and Pulmonary Arterial Hypertension.
Epidemiology of heart failure Darrel Francis Clinical Senior Lecturer in Cardiology Imperial College School of Medicine.
HEART FAILURE “pump failure”. DEFINITION Heart failure is the inability of the heart to supply adequate blood flow and therefore oxygen delivery.
Congestive heart failure
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
Heart Failure Whistle Stop Talks No 1 HFrEF and HFpEF Definitions for Diagnosis Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Dr. Meg-angela Christi M. Amores
Heart Failure Whistle Stop Talks No. 2 Classification Implications Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
HEART FAILURE PROF. DR. MUHAMMAD AKBAR CHAUDHRY M.R.C.P.(U.K) F.R.C.P.(E) F.R.C.P.(LONDON) F.A.C.C. DESIGNED AT A.V. DEPTT F.J.M.C. BY RABIA KAZMI.
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
HEART FAILURE Prevalence increasing in our ageing population Incidence doubles with each decade between 40 and 80 At any age more common in men than women.
L References Application to Clinical Practice The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have cooperatively.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
Heart Failure: From Failure to Success
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
Treatment of Heart Failure: Beyond Medical Therapy
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Background, recognition and differentials. By Dr L Axten.
The burden Of heart failure
To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Clinical Symptoms of Atrial Fibrillation in Different Ranges of QRS Duration Burda I.Yu., Yabluchansky N.I. Medical Clinics Chair National University of.
Cardiac Failure Richard Price Richard Price Consultant, Intensive Care, RAH. Consultant, Intensive Care, RAH.
Chronic Heart Failure – An Update T P Chua Royal Surrey County Hospital, Guildford St George’s Hospital, London.
New Technologies & Challenges in optimizing the “heart health” of Australia Professor Simon Stewart Head, Preventative Cardiology
Haissam A Haddad, MD, FRCPC, FACC University of Ottawa Heart Institute
Congestive Heart Failure Symptoms & signs
Internal Medicine Workshop Series Laos September /October 2009
THE NATURAL HISTORY OF DILATED CARDIOMYOPATHY (DCM) Thomas Zegkos Cardiomyopathies Lab AHEPA University Hospital.
Palpitations & Atrial Fibrillation Dr Mehul B Dhinoja, Consultant Cardiologist & Electrophysiologist BMI The London Independent Hospital.
Heart failure. Heart failure is a cardiac condition, that occurs when a problem with the structure or function of the heart impairs its ability to supply.
HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),
To know more visit HeartFailure.com © 2016 Novartis Pharma AG, July 2016, GLCM/HTF/0028c HEART FAILURE DISEASE MANAGEMENT STANDARDS.
Clinical Knowledge Summaries CKS Heart failure - chronic
Dr Dylan Harris Dr Mel Jefferson
Chronic heart failure By Vishal Patel GPVTS1.
Fig ACCF/AHA Guideline for the management of heart failure
DIAGNOSIS No symptoms = no heart failure. DIAGNOSIS No symptoms = no heart failure.
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotensinconvertingenzyme; ARB, angiotensin receptor blocker; CRT-D,
Treatment options for patients with chronic symptomatic systolic heart failure. ACE, angiotens inconverting enzyme; ARB, angiotensin receptor blocker;
– р<0.05 between baseline
Heart and Circulatory Failure
Figure 1 Diagnostic flowchart for patients with suspected heart failure—showing alternative ‘echocardiography first’ (blue) or ‘natriuretic peptide first’
Heart Failure Management
Dike Ojji Senior Lecturer
Treatment of Heart Failure With Preserved Ejection Fraction: Have We Been Pursuing the Wrong Paradigm?  Gerard O. Oghlakian, MD, Ilke Sipahi, MD, James.
Congestive heart failure
Heart Failure Prognosis & Management
11/18/2018 CHF Update 2018 Peter M. Lewis, DO FACC 1 1.
Diabetes Mellitus and Heart Failure
Nat. Rev. Cardiol. doi: /nrcardio
Congestive Heart Failure
Treatment of Heart Failure With Preserved Ejection Fraction: Have We Been Pursuing the Wrong Paradigm?  Gerard O. Oghlakian, MD, Ilke Sipahi, MD, James.
Take home figure The 38% of heart failure reduced ejection fraction (HFrEF) patients who recovered LVEF (HFrecEF) were more ... Take home figure The 38%
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Percentage distribution of ESC HF subtypes and no cardiac dysfunction (no dysf, n=38) among all 370 included patients, where HFvhd is HF due to valvular.
Rick A. Nishimura et al. JACC 2017;70:
Presentation transcript:

Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH

HF Definition Multiple and inadequate definitions “Inability of the heart (cardiac pump) to deliver adequate oxygenation (via blood flow) to tissues” Different types (and definitions): Acute vs. Chronic Left vs. Right Symptomatic vs. Asymptomatic Systolic vs. Diastolic

Definition of Heart Failure Classification Ejection Fraction Description I. Heart Failure with Reduced Ejection Fraction (HFrEF) ≤40% Also referred to as systolic HF. Randomized clinical trials have mainly enrolled patients with HFrEF and it is only in these patients that efficacious therapies have been demonstrated to date. II. Heart Failure with Preserved Ejection Fraction (HFpEF) ≥50% Also referred to as diastolic HF. Several different criteria have been used to further define HFpEF. The diagnosis of HFpEF is challenging because it is largely one of excluding other potential noncardiac causes of symptoms suggestive of HF. To date, efficacious therapies have not been identified. a. HFpEF, Borderline41% to 49% These patients fall into a borderline or intermediate group. Their characteristics, treatment patterns, and outcomes appear similar to those of patient with HFpEF. b. HFpEF, Improved>40%It has been recognized that a subset of patients with HFpEF previously had HFrEF. These patients with improvement or recovery in EF may be clinically distinct from those with persistently preserved or reduced EF. Further research is needed to better characterize these patients.

Epidemiology Increasing in prevalence Affects 1-2% of UK population Estimated 2-5% population over 65 years (10% over 75 years) Many undiagnosed Commoner in Western world Major burden on health care resources Worse prognosis than many forms of cancer

The prognosis of heart failure is as bad as for many cancers British Heart Foundation, 2002 One year survival rate %

Kaplan–Meier curves showing the effect of heart failure and left ventricular systolic dysfunction on survival. F.D. Richard Hobbs et al. Eur Heart J 2007;28: © The European Society of Cardiology All rights reserved. For Permissions, please

NYHA functional classification, 1964 Class INo limitations on activity. No fatigue, breathlessness or palpitation on ordinary physical activity Annual mortality 3-5% Class IIPatients are comfortable at rest but ordinary physical activity such as climbing stairs or doing housework results in symptoms ‘Mild’ heart failure Annual mortality 10% Class IIIPatients have a marked limitation of physical activity. Although patients are comfortable at rest, less than ordinary physical activity will lead to symptoms ‘Moderate’ heart failure Annual mortality 12-16% Class IVPatients have symptoms even at rest and are unable to undertake any physical activity without discomfort ‘Severe’ heart failure Annual mortality 15-20% Worse prognosis than most cancers

Aetiology Commonest cause is IHD Other Causes: Dilated Cardiomyopathy HBP (LVH) viral (post myocarditis), valvular disease, drugs, alcohol, thyroid disease Arrhythmia Chronic RV pacing

CardiacNoncardiac  Heart failure, including RV syndromes  Acute coronary syndrome  Heart muscle disease, including LVH  Valvular heart disease  Pericardial disease  Atrial fibrillation  Myocarditis  Cardiac surgery  Cardioversion  Advancing age  Anaemia  Renal failure  Pulmonary causes: obstructive sleep apnea, severe pneumonia, pulmonary hypertension  Critical illness  Bacterial sepsis  Severe burns  Toxic-metabolic insults, including cancer chemotherapy and envenomation Causes for Elevated Natriuretic Peptide Levels

Device Therapy for Heart Failure (also known as CRT or BiV)

LBBB

Table 1 Treatment options with ICD or CRT for people with heart failure who have left ventricular dysfunction with an LVEF of 35% or less (according to NYHA class, QRS duration and presence of LBBB)

Summary CHF is a growing problem Diagnosis can be difficult BNP used as a screening test – not a replacement for echocardiography Ensure optimal medical therapy including new treatments Perform ECG to see if there is a device option